Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Gandhi, A. K.
  • Mendy, D.
  • Waldman, M.
  • Chen, G.
  • Rychak, E.
  • Miller, Karen
  • Gaidarova, S.
  • Ren, Y.
  • Wang, M.
  • Breider, M.
  • Carmel, G.
  • Mahmoudi, A.
  • Jackson, P.
  • Abbasian, M.
  • Cathers, B. E.
  • Schafer, P. H.
  • Daniel, T. O.
  • Lopez-Girona, A.
  • Thakurta, A.
  • Chopra, R.

publication date

  • January 2014

journal

  • British Journal of Haematology  Journal

subject areas

  • Alternative Splicing
  • Antibodies, Monoclonal
  • Antibody Specificity
  • Biomarkers, Tumor
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm
  • Humans
  • Multiple Myeloma
  • Peptide Hydrolases
  • RNA Isoforms
  • Thalidomide
scroll to property group menus

Research

keywords

  • DNA damage binding protein 1
  • cereblon
  • cullin 4 ring ligase complex
  • immunomodulatory drugs
  • myeloma
scroll to property group menus

Identity

PubMed Central ID

  • PMC4253085

International Standard Serial Number (ISSN)

  • 0007-1048

Digital Object Identifier (DOI)

  • 10.1111/bjh.12622

PubMed ID

  • 24206017
scroll to property group menus

Additional Document Info

start page

  • 233

end page

  • 244

volume

  • 164

issue

  • 2

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support